Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Use May Shift Under US Medicare Oncology Care Model; Here’s How

Executive Summary

‘Episode of care’ payment model could reduce off-label cancer drug prescribing but also offers an opportunity for increased use of high-value drugs, including those that can reduce costs by decreasing hospitalizations, University of Chicago’s Rena Conti suggests.

You may also be interested in...



The 800-Lb. Gorilla: Drug Costs Loom Large In Medicare Oncology Care Model

Drug costs make up 60% of the total cost of cancer care, participants in the Medicare Oncology Care Model have found. But efforts to manage spending under the demonstration have so far focused instead on areas that represent a smaller portion of overall costs, such as hospitalizations.

US Medicare Oncology Demo Should Test Value-Based Drug Pricing – Providers

Community Oncology Alliance proposes updates to the Oncology Care Model demonstration project, including a sharper focus on lowering prescription drug costs.

Value-Based Payment Experiments For Drugs To Be Key Focus For CMMI, Director Says

Recently-installed Center for Medicare and Medicaid Innovation Chief Adam Boehler says payment lab will play a role in the Administration’s overall approach to lowering prescription drug costs.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS119421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel